ReviewJournal of cachexia, sarcopenia and muscle2016
Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective.
Review in Journal of cachexia, sarcopenia and muscle, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it, 147 citations in OpenAlex.
- Risk Factors of Sarcopenia in COPD Patients: A Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2024Pooled it
- THE EFFECT OF A SINGLE ORAL DOSE OF L-ARGININE ON QUADRICEPS STRENGTH IN SMOKERS AND NON-SMOKERS: A NON-RANDOMIZED CLINICAL TRIAL.Acta clinica Croatica · 2024Trial
- Vitamin DJournal of cachexia, sarcopenia and muscle · 2021Trial
- Fortified whey beverage for improving muscle mass in chronic obstructive pulmonary disease: a single-blind, randomized clinical trial.Respiratory research · 2020Trial
- Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients.PloS one · 2019Trial
- Skeletal Muscle Dysfunction and Exercise Intolerance in COPD and Idiopathic Pulmonary Fibrosis: Extracellular Vesicles as Candidate Mediators of a Lung-Muscle Axis.Muscles (Basel, Switzerland) · 2026Review
- The Evolving Landscape of COPD Typization.Medicina (Kaunas, Lithuania) · 2026Review
- The lung-muscle axis in COPD: a conceptual framework integrating evidence, mechanisms, and therapeutic perspectives.Frontiers in immunology · 2026Review
- The independent and combined effects of smoking and chronic obstructive pulmonary disease on body mass index trajectories.Scientific reports · 2025Article
- Cachexia Phenotyping Through Morphofunctional Assessment and Mitocondrial Biomarkers (GDF-15 and PGC-1α) in Idiopathic Pulmonary Fibrosis.Nutrients · 2025Observational
- Sarcopenia in chronic obstructive pulmonary disease: mechanisms, diagnosis, and management strategies.Annals of medicine and surgery (2012) · 2025Review
- A role of arginase-1-expressing myeloid cells in cachexia.Cancer & metabolism · 2025Article
- Metabolic dysfunction-associated steatotic liver disease: an emerging comorbidity in COPD.Therapeutic advances in chronic disease · 2025Review
- The Power of Drosophila in Modeling Cancer Cachexia.Advances in experimental medicine and biology · 2025Review
- Association of Nutritional Intake with Physical Activity and Handgrip Strength in Individuals with Airflow Limitation.Tuberculosis and respiratory diseases · 2025Article
- Loss of appetite in patients with chronic obstructive pulmonary disease - a mixed methods study.European clinical respiratory journal · 2025Article
- Skin Markers of Premature Ageing in Patients with COPD: Results Form COSYCONET.Journal of clinical medicine · 2024Article
- Genetically Predicted Body Mass Index and Mortality in Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2024Article
- Lipolysis engages CD36 to promote ZBP1-mediated necroptosis-impairing lung regeneration in COPD.Cell reports. Medicine · 2024Article
- Testosterone replacement therapy in patients with cachexia: a contemporary review of the literature.Sexual medicine reviews · 2024Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cachexia and muscle wasting are well recognized as common and partly reversible features of chronic obstructive pulmonary disease (COPD), adversely affecting disease progression and prognosis. This argues for integration of weight and muscle maintenance in patient care. In this review, recent insights are presented in the diagnosis of muscle wasting in COPD, the pathophysiology of muscle wasting, and putative mechanisms involved in a disturbed energy balance as cachexia driver. We discuss the therapeutic implications of these new insights for optimizing and personalizing management of COPD-induced cachexia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.